<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02009800</url>
  </required_header>
  <id_info>
    <org_study_id>ICI-VPH-1</org_study_id>
    <nct_id>NCT02009800</nct_id>
  </id_info>
  <brief_title>ICI-VPH: Impact of HPV Immunisation Schedules Against HPV</brief_title>
  <acronym>ICI-VPH</acronym>
  <official_title>ICI-VPH: Impact Des Calendriers d'Immunisation Contre Les HPV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Quebec-Universite Laval</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quebec Public Health National Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quebec Ministry of Health and Social Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CHU de Quebec-Universite Laval</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomised clinical trial aims to determine whether an immunization schedule comprising
      two doses of Gardasil administered six months apart is non-inferior to a schedule comprising
      three doses administered at 0, 6 and 60 months for the prevention of HPV-16 and HPV-18
      infections that persist for at least six months, up to ten years after the initial
      vaccination.

      The study hypothesis is that the two-dose schedule would offer similar protection as that of
      a three-dose schedule against persistent HPV-16/18 infections.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of persistent HPV-16/18 infections</measure>
    <time_frame>5 years after recruitment visite</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titres of antibodies and seropositivity for HPV types 6, 11, 16 and 18</measure>
    <time_frame>5 years after recruitment visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3364</enrollment>
  <condition>Human Papillomavirus Infections</condition>
  <arm_group>
    <arm_group_label>2 dose of quadrivalent HPV vaccine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The participants who have already received 2 doses of the quadrivalent HPV vaccine (0, 6 months schedule) 5 years before recruitment will not receive an additional dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 doses of quadrivalent HPV vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The participants will receive a 3rd dose of quadrivalent HPV vaccine at recruitment visit, which is 5 years after having received two doses of vaccine given 6 months apart in grade 4 (0, 6, 60 months Schedule)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent HPV vaccine</intervention_name>
    <description>One dose of Gardasil administered in the intervention group</description>
    <arm_group_label>3 doses of quadrivalent HPV vaccine</arm_group_label>
    <other_name>Gardasil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having received two doses of Gardasil in 2008-2009, 2009-2010,2010-2011 or 2011-2012
             according to 0, 6 months Schedule (between 4 and 12 months)

          -  Resident of the regions chosen for the study

        Exclusion Criteria:

          -  Being considered immunosuppressed at time of vaccination (9-10 years-old) or at
             recruitment visit

          -  Being pregnant at recruitment visit
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Hospitalier Uiversitaire de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Québec, CHU de Québec</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2013</study_first_posted>
  <last_update_submitted>March 2, 2017</last_update_submitted>
  <last_update_submitted_qc>March 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CHU de Quebec-Universite Laval</investigator_affiliation>
    <investigator_full_name>Chantal Sauvageau</investigator_full_name>
    <investigator_title>Co-principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

